Solian 400 mg film-coated tablets
Spain
Table of Contents
- Package leaflet: Information for the user
- Introduction
- 1. What Solian 400 mg is and what it is used for
- 2. What you need to know before taking Solian 400 mg
- **Use in children**
- 3. How to take Solian 400 mg
- 4. Possible adverse effects
- 5. Storage of Solian 400 mg tablets
- 6. Contents of the pack and other information
Package leaflet: Information for the user
Introduction
Package leaflet: information for the patient
Solian 400 mg film-coated tablets
Amisulpride
Read all of this leaflet carefully before you start taking this medicine, because it contains important information for you.
-
Keep this leaflet, as you may need to read it again.
-
If you have any questions, ask your doctor or pharmacist.
-
This medicine has been prescribed for you only, and you should not give it to other people, even if they have the same symptoms as you, because it could harm them.
-
If you experience any adverse effects, consult your doctor, pharmacist, or nurse, even if these effects are not listed in this leaflet. See section 4.
Contents of the leaflet
- What Solian 400 mg is and what it is used for
- What you need to know before taking Solian 400 mg
- How to take Solian 400 mg
- Possible side effects
- How to store Solian 400 mg
- Contents of the pack and other information
1. What Solian 400 mg is and what it is used for
Amisulpride belongs to a group of medicines called antipsychotics.
Solian 400 mg is indicated for the treatment of schizophrenia.
2. What you need to know before taking Solian 400 mg
Do not take Solian 400 mg tablets
- if you are allergic to the active substance or to any of the other ingredients of this medicine (listed in section 6).
- if you have a tumor dependent on prolactin (a hormone secreted by the anterior pituitary gland that stimulates milk production in the mammary glands), for example, pituitary prolactinomas or breast cancer.
- if you have phaeochromocytoma (a tumor of the adrenal gland).
- if you are a child, up to puberty.
- if you are being treated with levodopa.
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before starting to take Solian 400 mg,
- as with other antipsychotic medicines, neuroleptic malignant syndrome (a potentially fatal complication) may occur, characterized by high fever, muscle rigidity, nervous system disturbances (autonomic instability), altered consciousness (obnubilation), rhabdomyolysis (muscle breakdown associated with muscle pain), and increased levels of an enzyme called creatine phosphokinase (CPK). In cases of high fever, especially when high doses are used, all antipsychotic medications including amisulpride should be discontinued.
Rhabdomyolysis has also been observed in patients without neuroleptic malignant syndrome.
-
if you have Parkinson's disease.
-
if you have known cardiovascular disease or a family history of QT interval prolongation, and the use of neuroleptic medicines should be avoided.
-
if you have risk factors for stroke.
-
in elderly patients with psychosis associated with dementia who are being treated with antipsychotics (increased risk of death).
-
in patients with risk factors for thromboembolism (see section “Possible side effects”).
-
if you have a personal or family history of breast cancer.
-
if a pituitary tumor is diagnosed, treatment with amisulpride should be discontinued.
-
if you have an established diagnosis of diabetes mellitus or risk factors for diabetes.
-
if you have a history of seizures.
-
if you have renal impairment.
-
withdrawal symptoms (nausea, vomiting, or insomnia) have been reported after abrupt discontinuation of treatment at high doses. Psychotic symptoms and sudden onset of involuntary movement disorders such as akathisia (inability to remain still), dystonia (persistent involuntary contractions of muscles in one or more parts of the body), and dyskinesia (involuntary incoordination of movements) may also reappear. Therefore, gradual withdrawal is recommended.
-
as with other antipsychotic medicines, leukopenia, neutropenia, and agranulocytosis may occur. The onset of fever or unexplained infections may indicate these blood disorders (dyscrasias) (see section “Possible side effects”) and require immediate blood testing.
-
serious liver problems have been reported with Solian. Contact your doctor immediately if you experience fatigue, loss of appetite, nausea, vomiting, abdominal pain, or yellowing of the eyes or skin.
Taking Solian 400 mg with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might need to take any other medicines.
Certain medicines may alter the effect of Solian 400 mg, and therefore your doctor may adjust the dose during combined treatment.
The use of Solian 400 mg with levodopa is contraindicated.
Amisulpride may counteract the effects of dopaminergic agonists (e.g., bromocriptine and ropinirole).
The use of alcohol-containing medicines together with Solian 400 mg is not recommended, as amisulpride may enhance the central effects of alcohol.
It is important that you inform your doctor if you are currently taking any of the following medicines:
- Central nervous system depressants including narcotics, analgesics, sedating H1 antihistamines, barbiturates, benzodiazepines and other anxiolytics, clonidine and its derivatives.
- Medicines to lower blood pressure.
- Clozapine.
- Medicines that prolong the QT interval such as: antiarrhythmic medicines (quinidine, disopyramide, amiodarone, and sotalol), some antihistamines, other antipsychotics, and some medicines used to treat malaria (mefloquine).
- Lithium salts.
- Sucralfate.
- Antacids.
Taking Solian 400 mg with food and drinks
This medicine may enhance the effects of alcohol; therefore, alcoholic beverages are not recommended during treatment.
Pregnancy, breastfeeding, and fertility
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to become pregnant, consult your doctor or pharmacist before taking this medicine.
Pregnancy:
Solian is not recommended during pregnancy or in women of childbearing potential who are not using contraceptive methods.
If you take Solian during the last three months of pregnancy, your baby may experience agitation, muscle rigidity and/or muscle weakness, involuntary tremors, numbness, breathing difficulties, or feeding problems. If your baby develops any of these symptoms, you should contact your doctor.
Breastfeeding:
You must not breastfeed while being treated with Solian. Consult your doctor about the best way to feed your baby if you are taking Solian.
Use in children
The safety and efficacy of amisulpride have not been established in patients from puberty through 18 years of age: available data on the use of amisulpride in adolescents with schizophrenia are limited. Therefore, the use of amisulpride is not recommended from puberty through 18 years of age. In children before puberty, amisulpride is contraindicated.
Driving and use of machines
Solian 400 mg may cause symptoms such as drowsiness, dizziness, visual disturbances, blurred vision, and may reduce reaction capacity. These effects, as well as the underlying illness itself, may impair your ability to drive vehicles or operate machinery. Therefore, do not drive, operate machinery, or engage in other activities requiring special attention until your doctor has assessed your response to this medicine.
Solian 400 mg contains lactose
If your doctor has informed you of an intolerance to certain sugars, consult him before taking this medicine.
Solian 400 mg contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; hence, it is essentially "sodium-free".
3. How to take Solian 400 mg
Follow exactly the instructions given by your doctor or pharmacist for taking this medicine. If in doubt, consult your doctor or pharmacist again.
Remember to take your medicine. Your doctor will tell you how long to take the treatment and how to increase the dose. Do not stop treatment abruptly, as symptoms of your illness may reappear.
Solian 400 mg are tablets for oral administration.
Adults:
The dose should be adjusted according to your clinical response and tolerability to treatment.
A daily dose between 400 mg/day and 800 mg/day is recommended. In individual cases, the daily dose may be increased up to 1200 mg/day.
The daily dose should be taken as a single dose, or divided into two doses if the daily dose exceeds 400 mg/day.
Elderly patients:
Solian should be used with special caution due to the possible risk of hypotension (abnormally low blood pressure) and sedation. Your doctor will adjust the dose due to renal insufficiency.
Patients with renal insufficiency:
Your doctor will adjust the dose.
If you take more Solian 400 mg tablets than you should
Contact your doctor immediately or go to the nearest hospital.
In case of overdose or accidental ingestion, contact the Toxicology Information Service, telephone 91 562 04 20.
If you take more than the prescribed dose, symptoms such as drowsiness, sedation, and even coma, decreased blood pressure, and abnormal movements may occur. Cases of death have been reported, mainly when combined with other psychotropic agents.
If you forget to take Solian 400 mg tablets
Do not take a double dose to make up for missed doses.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
4. Possible adverse effects
Like all medicines, Solian 400 mg tablets may produce adverse effects, although not everyone experiences them.
If you experience any adverse effects, consult your doctor or pharmacist, even if these are adverse effects not listed in this leaflet.
The adverse effects observed according to their frequency of occurrence are: Very common (may affect more than 1 in 10 people); Common (may affect up to 1 in 10 people); Uncommon (may affect up to 1 in 100 people); Rare (may affect up to 1 in 1,000 people); Very rare (may affect up to 1 in 10,000 people); Frequency not known (cannot be estimated from the available data):
Blood and lymphatic system disorders:
Uncommon: Leukopenia (reduced number of white blood cells) and neutropenia (reduction in a type of white blood cells, neutrophils) (see section “Warnings and precautions”).
Rare: Agranulocytosis (reduction in a type of white blood cells, granulocytes) (see section “Warnings and precautions”).
Immune system disorders:
Uncommon: Allergic reactions.
Endocrine disorders:
Common: Milk secretion, absence of menstruation, breast enlargement (in males), breast pain, and erectile dysfunction.
Rare: Benign pituitary tumor such as prolactinoma (see sections “Do not take Solian” and “Warnings and precautions”).
Metabolism and nutrition disorders:
Uncommon: Hyperglycemia (increased blood glucose levels) (see section “Warnings and precautions”), increased blood triglycerides and cholesterol.
Rare: Hyponatremia and syndrome of inappropriate antidiuretic hormone secretion.
Psychiatric disorders:
Common: Insomnia, anxiety, agitation, orgasmic dysfunction.
Uncommon: Confusion.
Nervous system disorders:
Very common: Tremor, rigidity, poverty of movements, increased salivation, inability to remain still while sitting, and lack of coordination.
Common: Acute dystonia (torticollis, oculogyric crisis (involuntary deviation of gaze to one side), contraction of masticatory muscles) and somnolence.
Uncommon: Rhythmic, involuntary movements of the tongue and/or face after long-term administration, and epileptic seizures.
Rare: Neuroleptic malignant syndrome, a potentially fatal complication (see section “Warnings and precautions”).
Frequency not known: Restless legs syndrome (unpleasant sensation in the legs, temporarily relieved by movement, and symptoms worsen toward the end of the day).
Eye disorders:
Common: Blurred vision (see section “Driving and use of machines”).
Cardiac disorders:
Uncommon: Bradycardia (slowing of heart rate).
Rare: QT interval prolongation, ventricular arrhythmias such as torsades de pointes, ventricular tachycardia, which may lead to ventricular fibrillation or cardiac arrest, sudden death (see section “Warnings and precautions”).
Vascular disorders:
Common: Hypotension.
Uncommon: Increase in blood pressure.
Rare: Venous thromboembolism (a condition characterized by blood clotting in veins), including pulmonary embolism, sometimes fatal, and deep vein thrombosis (see section “Warnings and precautions”).
Respiratory, thoracic and mediastinal disorders:
Uncommon: Nasal congestion and aspiration pneumonia (mainly associated with other antipsychotics and central nervous system depressants).
Gastrointestinal disorders:
Common: Constipation, nausea, vomiting, dry mouth.
Hepatobiliary disorders:
Uncommon: Liver tissue damage.
Skin and subcutaneous tissue disorders:
Rare: Angioedema (generalized urticaria accompanied by swelling of feet, hands, throat, lips, and respiratory tract) and urticaria.
Frequency not known: Increased sensitivity of your skin to sunlight and ultraviolet light (photosensitivity).
Musculoskeletal and connective tissue disorders:
Uncommon: Bone disorders (osteopenia, osteoporosis).
Frequency not known: Rhabdomyolysis (muscle breakdown associated with muscle pain).
Renal and urinary disorders:
Uncommon: Urinary retention.
Pregnancy, puerperium and perinatal disorders:
Frequency not known: Withdrawal syndrome in newborns (see section “Pregnancy and breastfeeding”).
Investigations:
Common: Weight gain.
Uncommon: Increased liver enzymes, mainly transaminases.
Frequency not known: Elevated levels of creatine phosphokinase (a blood test indicating muscle damage).
Injury, poisoning and procedural complications:
Frequency not known: Falls due to reduced body balance, which sometimes result in fractures.
Important: You must seek immediate medical attention if:
- You experience any of the following symptoms while being treated with Solian 400 mg tablets: high fever, generalized muscle rigidity, rapid breathing, abnormal sweating, or decreased mental alertness, a potentially fatal condition known as neuroleptic malignant syndrome (see section “Warnings and precautions”).
- You notice an irregular heartbeat, dizziness, vertigo, difficulty breathing, or chest pain, as isolated cases have been reported of: serious ventricular arrhythmias such as torsade de pointes, ventricular tachycardia which may lead to atrial fibrillation or cardiac arrest, and fatal outcome (see section “Warnings and precautions”).
Reporting of Adverse Effects
If you experience any type of adverse effect, consult your doctor or pharmacist, even if they are possible adverse effects not listed in this leaflet. You may also report them directly via the Spanish Pharmacovigilance System for Human Medicines: https://www.notificaram.es. By reporting adverse effects, you can help provide more information on the safety of this medicine.
5. Storage of Solian 400 mg tablets
No special storage conditions are required.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month indicated.
Medicines must not be disposed of via wastewater or household waste. Dispose of containers and unused medicines at the SIGRE Point located at your pharmacy. If in doubt, ask your pharmacist how to dispose of containers and medicines you no longer need. This will help protect the environment.
6. Contents of the pack and other information
Composition of Solian 400 mg
-
The active substance is amisulpride.
-
The other components are:
Core: sodium carboxymethyl starch, lactose monohydrate, microcrystalline cellulose, hydroxypropylmethylcellulose and magnesium stearate.
Coating: hydroxypropylmethylcellulose, microcrystalline cellulose, polyethylene glycol 2000 monostearate and titanium dioxide (E171).
Appearance of the product and contents of the pack
Solian 400 mg is presented in the form of tablets. Each pack contains 30 white, oblong, scored tablets.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder:
sanofi-aventis, S.A.
C/ Rosselló i Porcel, 21
08016 Barcelona
Spain
Manufacturer:
Delpharm Dijon
6, Boulevard de l’Europe 21800
Quétigny (France)
Date of the most recent revision of this leaflet: June 2023
Detailed information on this medicine is available on the website of the Spanish Agency of Medicines and Health Products (AEMPS) http://www.aemps.gob.es/